Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. Fundamental Analysis
Agios Pharmaceuticals, Inc. (AGIO) shows moderate financial fundamentals with a PE ratio of -3.81, profit margin of -7.64%, and ROE of -31.07%. The company generates $0.1B in annual revenue with strong year-over-year growth of 36.07%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -564.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze AGIO's fundamental strength across five key dimensions:
Efficiency Score
WeakAGIO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentAGIO trades at attractive valuation levels.
Growth Score
ModerateAGIO shows steady but slowing expansion.
Financial Health Score
ExcellentAGIO maintains a strong and stable balance sheet.
Profitability Score
WeakAGIO struggles to sustain strong margins.
Key Financial Metrics
Is AGIO Expensive or Cheap?
P/E Ratio
AGIO trades at -3.81 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, AGIO's PEG of 1.65 indicates fair valuation.
Price to Book
The market values Agios Pharmaceuticals, Inc. at 1.32 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -3.71 times EBITDA. This is generally considered low.
How Well Does AGIO Make Money?
Net Profit Margin
For every $100 in sales, Agios Pharmaceuticals, Inc. keeps $-7.64 as profit after all expenses.
Operating Margin
Core operations generate -8.74 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-31.07 in profit for every $100 of shareholder equity.
ROA
Agios Pharmaceuticals, Inc. generates $-31.82 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Agios Pharmaceuticals, Inc. generates limited operating cash flow of $-374.53M, signaling weaker underlying cash strength.
Free Cash Flow
Agios Pharmaceuticals, Inc. generates weak or negative free cash flow of $-378.86M, restricting financial flexibility.
FCF Per Share
Each share generates $-6.47 in free cash annually.
FCF Yield
AGIO converts -23.82% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-3.81
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.65
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.32
vs 25 benchmark
P/S Ratio
Price to sales ratio
29.20
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
11.46
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.31
vs 25 benchmark
ROA
Return on assets percentage
-0.32
vs 25 benchmark
ROCE
Return on capital employed
-0.39
vs 25 benchmark
How AGIO Stacks Against Its Sector Peers
| Metric | AGIO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -3.81 | 29.43 | Better (Cheaper) |
| ROE | -31.07% | 692.00% | Weak |
| Net Margin | -764.01% | -44295.00% (disorted) | Weak |
| Debt/Equity | 0.03 | 0.35 | Strong (Low Leverage) |
| Current Ratio | 11.46 | 4.48 | Strong Liquidity |
| ROA | -31.82% | -18045.00% (disorted) | Weak |
AGIO outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Agios Pharmaceuticals, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-67.31%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
279.40%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-11.09%
Industry Style: Defensive, Growth, Innovation
Declining